Navigation Links
Novel approach strips staph of virulence
Date:2/14/2008

An international team of researchers supported by the National Institutes of Health (NIH) has blocked staph infections in mice using a drug previously tested in clinical trials as a cholesterol-lowering agent. The novel approach, described in the February 14 online edition of Science, could offer a new direction for therapies against a bacterium thats becoming increasingly resistant to antibiotics.

By following their scientific instinct about a basic biological process, the researchers made a surprising discovery with important clinical implications, said NIH Director Elias A. Zerhouni, M.D. Although the results are still very preliminary, they offer a promising new lead for developing drugs to treat a very timely and medically important health concern.

This work was supported by three NIH components: the National Institute of General Medical Sciences, the National Institute of Allergy and Infectious Diseases, and the National Institute of Child Health and Human Development.

A pigment similar to the one that gives carrots their color turns Staphylococcus aureus (staph) golden. In the bacterium, this pigment acts as an antioxidant to block the reactive oxygen molecules the immune system uses to kill bacteria.

Researchers had speculated that blocking pigment formation in staph could restore the immune systems ability to thwart infection. While perusing a magazine on microbial research, Eric Oldfield, Ph.D., of the University of Illinois at Urbana-Champaign read how in 2005 University of California, San Diego researchers knocked out a gene in staphs pigment-making pathway to create colorlessand less pathogenicbacteria.

I looked at the metabolic pathway and noticed that it was similar to the one for the production of cholesterol in humans, said Oldfield, senior author of the Science paper, who had spent decades studying this pathway. With numerous cholesterol-lowering drugs already on the market and in development, he wondered if any could turn staph colorless and make them once again susceptible to the immune system.

Colleagues in Taiwan determined the structure of the enzyme that triggers the first critical step in staphs pigment formation and observed striking similarities to an enzyme involved in human cholesterol production. They also captured the structures of several cholesterol-lowering drugs bound to the bacterial enzyme.

Building on their 2005 research that sparked the current study, Victor Nizet, M.D., and George Liu, M.D., Ph.D., now at Cedars-Sinai Medical Center in Los Angeles, Calif., tested eight different drug compounds that act on the human cholesterol enzyme. Three blocked pigment production in laboratory tests. When the researchers treated mice infected with S. aureus with one of the compounds, the bacterial population was reduced by 98 percent.

Because the approach reduces the virulence of the bacteria by stopping pigment production, it may not cause selective pressures on the population, which can lead to antibiotic resistance. It also targets only S. aureus, possibly reducing side effects.

This is an entirely new approach that seems to work in animals, and now we need to take the next step to explore if it will work in humans, said Oldfield.


'/>"/>

Contact: Emily Carlson
carlsone@nigms.nih.gov
301-496-7301
NIH/National Institute of General Medical Sciences
Source:Eurekalert

Related medicine news :

1. UCSD research team identifies novel anticancer drug from the sea
2. Novel compound may lessen heart attack damage
3. Novel molecules developed at UB can boost vaccine potency
4. Novel small molecule therapy shows benefit for anemic patients via hydration of red blood cells
5. Novel vaccine concept developed by scientists at the Wistar Institute
6. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
7. Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology
8. Statement by AARP CEO Bill Novelli on President Bushs State of the Union
9. New method enables design, production of extremely novel drugs
10. Nerites Receives NIH Grant to Study Novel Treatment for Preventing Dangerous Bacterial Infections on Urinary Stents and Catheters
11. Speedy Procedures Demonstrate Excitement and Continued Interest in Novel Multi-Electrode Ablation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... office, will speak at the American Conference Institute’s 21st Drug & Medical Device ... a Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical ...
(Date:12/2/2016)... ... 2016 , ... Advanced Inc., a leading provider of travel therapy and travel ... serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served ... and operational leadership experience to Advanced Inc. He began his career in finance at ...
(Date:12/2/2016)... PITTSBURGH, PA (PRWEB) , ... December 02, 2016 , ... ... or struggling through rehabilitation of an injury, patients must find the one that works ... for his pain, he created a machine that worked and decided to share it ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... According to a new ... Product (Instruments, Reagents, Software), Technology (Immunoassay, Clinical Chemistry, ... Infectious Diseases) - Forecast to 2021" published by ... 60.22 Billion in 2016. This market is expected ... the forecast period (2016-2021) to reach USD 78.74 ...
(Date:12/2/2016)... On Thursday, December 1st 2016, the Prix ... and innovation in the biopharmaceutical industry at its third ... presence of Sergey Tsyb, Vice Minister of Industry and ... Natalia Sanina, First Vice Chairman of the State Duma ... National Service of Control in Healthcare, Sergey Muravev, Director ...
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, ein Weltführer ... bei den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
Breaking Medicine Technology: